3JD

2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide

Created: 2014-08-26
Last modified:  2020-06-05

Find related ligands:

Chemical Details

Formal Charge0
Atom Count44
Chiral Atom Count1
Bond Count47
Aromatic Bond Count16
2D diagram of 3JD

Chemical Component Summary

Name2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
SynonymsNiraparib
Systematic Name (OpenEye OEToolkits)2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
FormulaC19 H20 N4 O
Molecular Weight320.388
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs12.01O=C(c1cccc2cn(nc12)c3ccc(cc3)C4CCCNC4)N
SMILESCACTVS3.385NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[CH]4CCCNC4
SMILESOpenEye OEToolkits1.7.6c1cc2cn(nc2c(c1)C(=O)N)c3ccc(cc3)C4CCCNC4
Canonical SMILESCACTVS3.385 NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4
Canonical SMILESOpenEye OEToolkits1.7.6 c1cc2cn(nc2c(c1)C(=O)N)c3ccc(cc3)[C@@H]4CCCNC4
InChIInChI1.03 InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
InChIKeyInChI1.03 PCHKPVIQAHNQLW-CQSZACIVSA-N

Drug Info: DrugBank

DrugBank IDDB11793 
NameNiraparib
Groups
  • investigational
  • approved
DescriptionNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.[L43747]
Synonyms
  • Niraparib tosylate
  • Niraparib
  • Niraparib hydrochloride
  • Niraparib tosylate monohydrate
Brand Names
  • Akeega
  • Zejula
IndicationNiraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.[L43277, L43742, L43747] In Canada and the US, niraparib is also available in a combination product with [abiraterone], which is indicated with [prednisone] for the treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).[L46896, L47755] In Canada, this combination product is also used with [prednisolone] and is reserved for patients who are asymptomatic or mildly symptomatic, and in whom chemotherapy is not clinically indicated.[L46896]
Categories
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • BCRP/ABCG2 Inhibitors
  • BCRP/ABCG2 Substrates
  • Cytochrome P-450 CYP1A2 Inducers
ATC-CodeL01XK02
CAS number1038915-60-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Poly [ADP-ribose] polymerase 1MAESSDKLYRVEYAKSGRASCKKCSESIPKDSLRMAIMVQSPMFDGKVPH...unknowninhibitor
Poly [ADP-ribose] polymerase 2MAARRRRSTGGGRARALNESKRVNNGNTAPEDSSPAKKTRRCQRQESKKM...unknowninhibitor
Carboxylesterase

MWLRAFILATLSASAAW

unknownsubstrate
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknowninducer
Serum albuminMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...unknownbinder
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1094636
PubChem 24958200
ChEMBL CHEMBL1094636